Q2 2026 snapshot: 582 industry-sponsored, actively-recruiting trials. 141 unique sponsors. 194 new trials started in the last 12 months. Pick a TA below for the feasibility-relevant cut.
These landscape pages are written for VPs of Clinical, Heads of Clinical Operations, and Medical Affairs leaders evaluating Brazilian sites for a specific protocol. Each page uses real Q2 2026 ClinicalTrials.gov data for that TA: trial counts, regional distribution, named centers, and the subset of Brazil's 141 industry sponsors most active in the space.
Sponsor-by-TA granularity and competing-trial overlap details are in the full quarterly landscape report. Below — one-line blurbs and Q2 2026 trial counts by TA.
Solid tumors (188) and hematologic oncology (62) dominate Brazil's trial map. Barretos, HCPA, Sírio-Libanês, and the Porto Alegre academic cluster anchor recruitment.
Read the oncology landscape → 21 trials · 3.6% of footprintObesity, T2D, MASH, and rare endocrine programs. Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and emerging biotechs run Phase 3 Brazilian arms.
Read the metabolic landscape → 29 trials · 5.0% of footprintMS, Alzheimer's, migraine, ALS, and rare neurology. HCPA, São Lucas PUCRS, Moinhos de Vento, and Oswaldo Cruz anchor a tight academic bench.
Read the neurology landscape → 15 trials · 2.6% of footprintCrohn's, UC, eosinophilic esophagitis, MASH overlap. Site competition at a tight 6-center cluster is the dominant feasibility risk.
Read the IBD landscape → 11 trials · 1.9% of footprintPsoriasis, atopic dermatitis, HS, prurigo. São Paulo and Porto Alegre derm groups plus private research centers handle advanced-mechanism programs.
Read the dermatology landscape → 25 trials · 4.3% of footprintAlexion, Azafaros, Crinetics, Sanofi/Genzyme and big-pharma orphan franchises. HCPA's genetics service anchors patient-aggregation networks.
Read the rare-disease landscape →Brazil also runs active trials in cardiovascular (35), rheumatology (26), nephrology (24), pulmonology (20), infectious disease (11), psychiatry (9), and ophthalmology (3). If you have a protocol in one of these, send us the synopsis and we'll return a Brazil-specific feasibility memo. Request a memo →